Physician profile
John Mclain
NPI 1629368188
$2,084.45
in general payments reported to CMS, 2019-2025
14 companies · $497 in 2025
The $497 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $100 · 2021: $91.41 · 2022: $230 · 2023: $266 · 2024: $353 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $447.25 | 2021-2024 | Andexxa, Lokelma |
| Mallinckrodt Hospital Products INC. | $292.40 | 2025 | Terlivaz |
| Genentech USA, INC. | $251.51 | 2019 | |
| Janssen Pharmaceuticals, INC | $191.54 | 2019-2022 | |
| Stryker Corporation | $160.99 | 2025 | Flowtriever |
| Abbvie INC. | $138.71 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2019 | |
| Amgen INC. | $121.82 | 2024 | Tavneos |
| Grifols USA, LLC | $109.68 | 2024 | Hyperrab |
| Allergan, INC. | $100.00 | 2020 | |
| Vapotherm INC | $91.19 | 2019 | |
| Avanos Medical | $22.08 | 2025 | Pnb and Accessories |
| Axsome Therapeutics, INC. | $21.87 | 2025 | Auvelity |
| Rare Disease Therapeutics, INC. | $10.42 | 2023 | Anavip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.